4.4 Findings
4.4.1 Theme 1: Mandate to use Learning Management System
La vigencia de esta guía clínica es de 3 años y será sometida a revisión después de éste período o ante la aparición de nueva evidencia científica de relevancia.
REFERENCIAS
1. Departamento de Estadísticas e Información de Salud. Estadísticas Vitales. In: Ministerio de Salud, ed. Chile; 2008.
2. Programa Nacional de Cáncer Cérvico Uterino. In: Unidad de Cáncer, ed.: Ministerio de Salud.
3. Chiu M., Prieto M. Atlás interactivo de Mortalidad ajustada por cáncer cervicouterino años 1987-2005, comparación entre regiones: http://epi.minsal.cl/epi/html/AtlasInteractivos/AtlasCervicoUterino/atlas.html; 2007.
4. Formulario de Evaluación Programa Nacional de Cáncer Cervicouterino. In: Unidad de Cáncer, ed.: Ministerio de Salud,; 2006.
5. Bertran E, Jofre A, Flores ME. Registro Poblacional del Cancer. Provincia de Valdivia. Informe quinquenio 1998-2002: Servicio de Salud Valdivia. Ministerio de Salud; 2004.
6. Informe de Registro Poblacional Antofagasta.
7. U.S.Preventive Services Task Force Screening for cervical cancer: recommendations and rationale. Am Fam Physician. 2003;67:1759-1766. 8. Munoz N, Mendez F, Posso H, et al. Incidence, duration, and determinants
of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis. 2004;190:2077-2087.
9. Munoz N, Franceschi S, Bosetti C, et al. Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study.
Lancet. 2002;359:1093-1101.
10. Moreno V, Bosch FX, Munoz N, et al. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet. 2002;359:1085-1092.
11. Cogliano V, Grosse Y, Baan R, Straif K, Secretan B, El Ghissassi F. Carcinogenicity of combined oestrogen-progestagen contraceptives and menopausal treatment. Lancet Oncol. 2005;6:552-553.
12. Giuliano AR. The role of nutrients in the prevention of cervical dysplasia and cancer. Nutrition. 2000;16:570-573.
13. Shannon J, Thomas DB, Ray RM, et al. Dietary risk factors for invasive and in-situ cervical carcinomas in Bangkok, Thailand. Cancer Causes Control. 2002;13:691-699.
14. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst. 1995;87:796-802. 15. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of
human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518-527.
16. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12-19.
Research on Cancer. Cervix cancer screening : views and opinions of an
IARC Working Group on the Evaluation of Cancer-preventive Strategies, Lyon, 20-27 April 2004. Lyon: International Agency for Research on Cancer;
2005:302 s.
18. Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice.
J Natl Cancer Inst. 2005;97:1072-1079.
19. Winer RL, Kiviat NB, Hughes JP, et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis. 2005;191:731-738. 20. Dignan M, Michielutte R, Blinson K, et al. Effectiveness of health education
to increase screening for cervical cancer among eastern-band Cherokee Indian women in North Carolina. J Natl Cancer Inst. 1996;88:1670-1676. 21. Garcia-Closas R, Castellsague X, Bosch X, Gonzalez CA. The role of diet
and nutrition in cervical carcinogenesis: a review of recent evidence. Int J
Cancer. 2005;117:629-637.
22. Hodge FS, Stubbs HA, Gurgin V, Fredericks L. Cervical cancer screening: Knowledge, attitudes, and behavior of American Indian women. Cancer. 1998;83:1799-1804.
23. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial.
Lancet. 2006;367:1247-1255.
24. Rambout L, Hopkins L, Hutton B, Fergusson D. Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials. CMAJ. 2007;177:469-479.
25. Villa LL, Costa RL, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006;95:1459-1466. 26. La Torre G, de Waure C, Chiaradia G, Mannocci A, Ricciardi W. HPV
vaccine efficacy in preventing persistent cervical HPV infection: a systematic review and meta-analysis. Vaccine. 2007;25:8352-8358.
27. Olsson SE, Villa LL, Costa RL, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine. 2007;25:4931-4939.
28. Almonte M, Ferreccio C, Winkler JL, et al. Cervical screening by visual inspection, HPV testing, liquid-based and conventional cytology in Amazonian Peru. Int J Cancer. 2007;121:796-802.
29. Herrero R, Ferreccio C, Salmeron J, et al. New approaches to cervical cancer screening in Latin America and the Caribbean. Vaccine. 2008;26 Suppl 11:L49-58.
30. Koliopoulos G, Arbyn M, Martin-Hirsch P, Kyrgiou M, Prendiville W, Paraskevaidis E. Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of non- randomized studies. Gynecol Oncol. 2007;104:232-246.
31. Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J. Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. Vaccine. 2006;24 Suppl 3:S3/78-89.
32. Cuzick J, Mayrand MH, Ronco G, Snijders P, Wardle J. Chapter 10: New dimensions in cervical cancer screening. Vaccine. 2006;24 Suppl 3:S3/90- 97.
33. Kitchener HC, Castle PE, Cox JT. Chapter 7: Achievements and limitations of cervical cytology screening. Vaccine. 2006;24 Suppl 3:S3/63-70.
34. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 2002;287:2114- 2119.
35. Miller AB, Knight J, Narod S. The Natural History of Cancer of the Cervix Uteri, and the Implications for Screening Policies Cancer Screening. Cambridge: Cambridge University Press; 1991:144-152.
36. Sasieni P, Adams J, Cuzick J. Benefit of cervical screening at different ages: evidence from the UK audit of screening histories. Br J Cancer. 2003;89:88- 93.
37. Lewis J. Analisis de la situacion del cancer cerivouterino en America Latina y el Caribe. Washington, D.C.: OPS; 2004.
38. Kitchener HC, Castle PE, Cox JT. Chapter 7: Achievements and limitations of cervical cytology screening. Vaccine. 2006;24 Suppl 3:S63-70.
39. Madlensky L, Goel V, Polzer J, Ashbury FD. Assessing the evidence for organised cancer screening programmes. Eur J Cancer. 2003;39:1648- 1653.
40. Crum CP, Genest DR, Krane JF, et al. Subclassifying atypical squamous cells in Thin-Prep cervical cytology correlates with detection of high-risk human papillomavirus DNA. Am J Clin Pathol. 1999;112:384-390.
41. Kobelin MH, Kobelin CG, Burke L, Lavin P, Niloff JM, Kim YB. Incidence and predictors of cervical dysplasia in patients with minimally abnormal Papanicolaou smears. Obstet Gynecol. 1998;92:356-359.
42. Malik SN, Wilkinson EJ, Drew PA, Bennett BB, Hardt NS. Do qualifiers of ASCUS distinguish between low- and high-risk patients? Acta Cytol. 1999;43:376-380.
43. Sherman ME, Solomon D, Schiffman M. Qualification of ASCUS. A comparison of equivocal LSIL and equivocal HSIL cervical cytology in the ASCUS LSIL Triage Study. Am J Clin Pathol. 2001;116:386-394.
44. Slawson DC, Bennett JH, Simon LJ, Herman JM. Should all women with cervical atypia be referred for colposcopy: a HARNET study. Harrisburgh Area Research Network. J Fam Pract. 1994;38:387-392.
45. Solomon D, Schiffman M, Tarone R. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst. 2001;93:293-299.
46. Jones BA, Novis DA. Follow-up of abnormal gynecologic cytology: a college of American pathologists Q-probes study of 16132 cases from 306 laboratories. Arch Pathol Lab Med. 2000;124:665-671.
47. Lonky NM, Sadeghi M, Tsadik GW, Petitti D. The clinical significance of the poor correlation of cervical dysplasia and cervical malignancy with referral cytologic results. Am J Obstet Gynecol. 1999;181:560-566.
48. Wright TC, Jr., Cox JT, Massad LS, Twiggs LB, Wilkinson EJ. 2001 Consensus Guidelines for the Management of Women with Cervical Cytological Abnormalities. J Low Genit Tract Dis. 2002;6:127-143.
49. Hoskins WJ, et al. Principle and practice of gynecologic oncology. Second Edition ed: Lippincott-Raven; 1996.
50. Scottish Intercollegiate Guidelines Network. Management of cervical cancer. A national clinical guideline. In: Scottish Intercollegiate Guidelines Network, ed. NHS Quality Improvement Scotland; January 2008.
51. Ontario Cervical Screening Program, Gynecology Cancer Disease Site Group, McLachlin CM, et al. Cervical Screening. Toronto: Cancer Care Ontario; 2005:39.
52. American College of Obstetricians and Gynecologists (ACOG).
Management of abnormal cervical cytology and histology. Washington (DC):
American College of Obstetricians and Gynecologists (ACOG),; 2008.
53. Bigrigg MA, Codling BW, Pearson P, Read MD, Swingler GR. Colposcopic diagnosis and treatment of cervical dysplasia at a single clinic visit. Experience of low-voltage diathermy loop in 1000 patients. Lancet. 1990;336:229-231.
54. Brown FM, Faquin WC, Sun D, Crum CP, Cibas ES. LSIL biopsies after HSIL smears. Correlation with high-risk HPV and greater risk of HSIL on follow-up. Am J Clin Pathol. 1999;112:765-768.
55. Luesley DM, Cullimore J, Redman CW, et al. Loop diathermy excision of the cervical transformation zone in patients with abnormal cervical smears.
BMJ. 1990;300:1690-1693.
56. Martin-Hirsch P, Paraskevaidis E, Kitchener H. Cirugía para la neoplasia intraepitelial cervical. Cochrane Databes of Systematic Reviews. 2008. 57. Wright TC, Jr., Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon
D. 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. Am J Obstet Gynecol. 2007;197:340-345.
58. Kalliala I, Nieminen P, Dyba T, Pukkala E, Anttila A. Cancer free survival after CIN treatment: comparisons of treatment methods and histology.
Gynecol Oncol. 2007;105:228-233.
59. Kyrgiou M, Tsoumpou I, Vrekoussis T, et al. The up-to-date evidence on colposcopy practice and treatment of cervical intraepithelial neoplasia: the Cochrane colposcopy & cervical cytopathology collaborative group (C5 group) approach. Cancer Treat Rev. 2006;32:516-523.
60. Nuovo J, Melnikow J, Willan AR, Chan BK. Treatment outcomes for squamous intraepithelial lesions. Int J Gynaecol Obstet. 2000;68:25-33. 61. Soutter WP, Sasieni P, Panoskaltsis T. Long-term risk of invasive cervical
cancer after treatment of squamous cervical intraepithelial neoplasia. Int J
62. Schlecht NF, Platt RW, Duarte-Franco E, et al. Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. J Natl Cancer Inst. 2003;95:1336-1343.
63. Nobbenhuis MA, Helmerhorst TJ, van den Brule AJ, et al. Cytological regression and clearance of high-risk human papillomavirus in women with an abnormal cervical smear. Lancet. 2001;358:1782-1783.
64. Alvarez RD, Wright TC. Effective cervical neoplasia detection with a novel optical detection system: a randomized trial. Gynecol Oncol. 2007;104:281- 289.
65. Dunn TS, Burke M, Shwayder J. A "see and treat" management for high- grade squamous intraepithelial lesion pap smears. J Low Genit Tract Dis. 2003;7:104-106.
66. Massad LS, Collins YC, Meyer PM. Biopsy correlates of abnormal cervical cytology classified using the Bethesda system. Gynecol Oncol. 2001;82:516-522.
67. Melnikow J, Nuovo J, Willan AR, Chan BK, Howell LP. Natural history of cervical squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol. 1998;92:727-735.
68. Mitchell MF, Tortolero-Luna G, Wright T, et al. Cervical human papillomavirus infection and intraepithelial neoplasia: a review. J Natl
Cancer Inst Monogr. 1996:17-25.
69. Robertson AJ, Anderson JM, Beck JS, et al. Observer variability in histopathological reporting of cervical biopsy specimens. J Clin Pathol. 1989;42:231-238.
70. Azodi M, Chambers SK, Rutherford TJ, Kohorn EI, Schwartz PE, Chambers JT. Adenocarcinoma in situ of the cervix: management and outcome.
Gynecol Oncol. 1999;73:348-353.
71. Krivak TC, Rose GS, McBroom JW, Carlson JW, Winter WE, 3rd, Kost ER. Cervical adenocarcinoma in situ: a systematic review of therapeutic options and predictors of persistent or recurrent disease. Obstet Gynecol Surv. 2001;56:567-575.
72. Soutter WP, Haidopoulos D, Gornall RJ, et al. Is conservative treatment for adenocarcinoma in situ of the cervix safe? BJOG. 2001;108:1184-1189. 73. Bigrigg A, Haffenden DK, Sheehan AL, Codling BW, Read MD. Efficacy and
safety of large-loop excision of the transformation zone. Lancet. 1994;343:32-34.
74. Paraskevaidis E, Arbyn M, Sotiriadis A, et al. The role of HPV DNA testing in the follow-up period after treatment for CIN: a systematic review of the literature. Cancer Treat Rev. 2004;30:205-211.
75. Persad VL, Pierotic MA, Guijon FB. Management of cervical neoplasia: a 13-year experience with cryotherapy and laser. J Low Genit Tract Dis. 2001;5:199-203.
76. Bornstein J, Schwartz J, Perri A, Harroch J, Zarfati D. Tools for post LEEP surveillance. Obstet Gynecol Surv. 2004;59:663-668.
77. Benedet JL, Bender H, Jones H, 3rd, Ngan HY, Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of
gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J
Gynaecol Obstet. 2000;70:209-262.
78. Loft A, Berthelsen AK, Roed H, et al. The diagnostic value of PET/CT scanning in patients with cervical cancer: a prospective study. Gynecol
Oncol. 2007;106:29-34.
79. Maruo T, Shibata K, Kimura A, Hoshina M, Mochizuki M. Tumor-associated antigen, TA-4, in the monitoring of the effects of therapy for squamous cell carcinoma of the uterine cervix. Serial determinations and tissue localization. Cancer. 1985;56:302-308.
80. Miller TR, Pinkus E, Dehdashti F, Grigsby PW. Improved prognostic value of 18F-FDG PET using a simple visual analysis of tumor characteristics in patients with cervical cancer. J Nucl Med. 2003;44:192-197.
81. Narayan K, Hicks RJ, Jobling T, Bernshaw D, McKenzie AF. A comparison of MRI and PET scanning in surgically staged loco-regionally advanced cervical cancer: potential impact on treatment. Int J Gynecol Cancer. 2001;11:263-271.
82. Ministerio de Salud. Guía Clínica de Cáncer Cérvico Uterino. In: Minsal. UdC, ed. 1st ed. Santiago; 2006.
83. National Cancer Institute. Cervical Cancer Treatment. Health Professional Version: National Cancer Institute. U.S. National Institutes of Health 2009. 84. Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant
hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med. 1999;340:1154-1161.
85. Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
N Engl J Med. 1999;340:1137-1143.
86. Peters WA, 3rd, Liu PY, Barrett RJ, 2nd, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 2000;18:1606-1613.
87. Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl
J Med. 1999;340:1144-1153.
88. Thomas GM. Improved treatment for cervical cancer--concurrent chemotherapy and radiotherapy. N Engl J Med. 1999;340:1198-1200.
89. Whitney CW, Sause W, Bundy BN, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol. 1999;17:1339-1348.
90. Green J, Kirwan J, Tierney J, et al. Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix. Cochrane Database Syst
Rev. 2005:CD002225.
91. Lukka H, Hirte H, Fyles A, et al. Concurrent cisplatin-based chemotherapy plus radiotherapy for cervical cancer--a meta-analysis. Clin Oncol (R Coll
92. National Cancer Institute. Concurrent chemoradiation for cervical cancer; 1999.
93. Board of the Faculty of Clinical Oncology. The Royal College of Radiologists. Guidelines for the Management of the Unscheduled Interruption or Prolongation of a Radical Course of Radiotherapy. In: The Royal College of Radiologists, ed. 2nd ed. London; 2002.
94. Creasman WT, Zaino RJ, Major FJ, DiSaia PJ, Hatch KD, Homesley HD. Early invasive carcinoma of the cervix (3 to 5 mm invasion): risk factors and prognosis. A Gynecologic Oncology Group study. Am J Obstet Gynecol. 1998;178:62-65.
95. NIH releases consensus statement on cervical cancer. Am Fam Physician. 1996;54:2310, 2315-2316.
96. Delgado G, Bundy B, Zaino R, Sevin BU, Creasman WT, Major F. Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol. 1990;38:352-357.
97. Jones WB, Mercer GO, Lewis JL, Jr., Rubin SC, Hoskins WJ. Early invasive carcinoma of the cervix. Gynecol Oncol. 1993;51:26-32.
98. Raspagliesi F, Ditto A, Solima E, et al. Microinvasive squamous cell cervical carcinoma. Crit Rev Oncol Hematol. 2003;48:251-261.
99. Sevin BU, Nadji M, Averette HE, Hilsenbeck S, Smith D, Lampe B. Microinvasive carcinoma of the cervix. Cancer. 1992;70:2121-2128.
100. Smith HO, Qualls CR, Romero AA, et al. Is there a difference in survival for IA1 and IA2 adenocarcinoma of the uterine cervix? Gynecol Oncol. 2002;85:229-241.
101. Mota F. Microinvasive squamous carcinoma of the cervix: treatment modalities. Acta Obstet Gynecol Scand. 2003;82:505-509.
102. Stegeman M, Louwen M, van der Velden J, et al. The incidence of parametrial tumor involvement in select patients with early cervix cancer is too low to justify parametrectomy. Gynecol Oncol. 2007;105:475-480.
103. Grigsby PW, Perez CA. Radiotherapy alone for medically inoperable carcinoma of the cervix: stage IA and carcinoma in situ. Int J Radiat Oncol
Biol Phys. 1991;21:375-378.
104. Hertel H, Kohler C, Grund D, et al. Radical vaginal trachelectomy (RVT) combined with laparoscopic pelvic lymphadenectomy: prospective multicenter study of 100 patients with early cervical cancer. Gynecol Oncol. 2006;103:506-511.
105. Plante M, Renaud MC, Hoskins IA, Roy M. Vaginal radical trachelectomy: a valuable fertility-preserving option in the management of early-stage cervical cancer. A series of 50 pregnancies and review of the literature. Gynecol
Oncol. 2005;98:3-10.
106. Koliopoulos G, Sotiriadis A, Kyrgiou M, Martin-Hirsch P, Makrydimas G, Paraskevaidis E. Conservative surgical methods for FIGO stage IA2 squamous cervical carcinoma and their role in preserving women's fertility.
Gynecol Oncol. 2004;93:469-473.
108. Halperin E, Perez CA, Brady LW. Perez and Brady's principles and practice
of radiation oncology. 5th ed. Philadelphia: J.B. Lippincott; 2008:xvi, 1544 p.
109. Hoskins W, Perez C, Young R, Barakat R, Markman M. Principles and
Practice of Gynecologic Oncology 4th ed: Lippincott Williams & Wilkins, ;
2004.
110. Landoni F, Maneo A, Colombo A, et al. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet. 1997;350:535- 540.
111. Follen M, Levenback CF, Iyer RB, et al. Imaging in cervical cancer. Cancer. 2003;98:2028-2038.
112. Hricak H, Yu KK. Radiology in invasive cervical cancer. AJR Am J
Roentgenol. 1996;167:1101-1108.
113. Piver MS, Chung WS. Prognostic significance of cervical lesion size and pelvic node metastases in cervical carcinoma. Obstet Gynecol. 1975;46:507-510.
114. Patel FD, Rai B, Mallick I, Sharma SC. High-dose-rate brachytherapy in uterine cervical carcinoma. Int J Radiat Oncol Biol Phys. 2005;62:125-130. 115. Viani GA, Manta GB, Stefano EJ, de Fendi LI. Brachytherapy for cervix
cancer: low-dose rate or high-dose rate brachytherapy - a meta-analysis of clinical trials. J Exp Clin Cancer Res. 2009;28:47.
116. Nag S, Chao C, Erickson B, et al. The American Brachytherapy Society recommendations for low-dose-rate brachytherapy for carcinoma of the cervix. Int J Radiat Oncol Biol Phys. 2002;52:33-48.
117. Nag S, Erickson B, Thomadsen B, Orton C, Demanes JD, Petereit D. The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for carcinoma of the cervix. Int J Radiat Oncol Biol Phys. 2000;48:201-211.
118. Baeza R, Olfos P, Suárez E. Resultados terapias combinadas en cáncer de cuello uterino de gran volumen Congreso Chil. Obstet. Ginecol.; 1999. 119. Rubin SC, Hoskins WJ. Cervical cancer and preinvasive neoplasia. Vol 189:
Lippincott-Raven; 1996.
120. Thoms WW, Jr., Eifel PJ, Smith TL, et al. Bulky endocervical carcinoma: a 23-year experience. Int J Radiat Oncol Biol Phys. 1992;23:491-499.
121. Monk BJ, Tewari KS, Koh WJ. Multimodality therapy for locally advanced cervical carcinoma: state of the art and future directions. J Clin Oncol. 2007;25:2952-2965.
122. Haie-Meder C, Fervers B, Chauvergne J, et al. [Concomitant radiochemotherapy for cancer of the cervix: critical analysis based on the Standards, Options and Recommendations methodology]. Cancer
Radiother. 2000;4:60-75.
123. International commission of radiation units and measurements I. Prescribing, recording and reporting photon beam therapy. In: ICRU, ed. Vol Report 50; 1993.
124. Rotman M, Choi K, Guse C, Marcial V, Hornback N, John M. Prophylactic irradiation of the para-aortic lymph node chain in stage IIB and bulky stage IB carcinoma of the cervix, initial treatment results of RTOG 7920. Int J
125. Rotman M, Pajak TF, Choi K, et al. Prophylactic extended-field irradiation of para-aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas. Ten-year treatment results of RTOG 79-20. JAMA. 1995;274:387-393.
126. Long HJ, 3rd, Bundy BN, Grendys EC, Jr., et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol. 2005;23:4626-4633. 127. Monk BJ, Huang HQ, Cella D, Long HJ, 3rd. Quality of life outcomes from a
randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group Study. J Clin Oncol. 2005;23:4617-4625.
128. Tewari KS, Monk BJ. Gynecologic oncology group trials of chemotherapy for metastatic and recurrent cervical cancer. Curr Oncol Rep. 2005;7:419-434. 129. Small W, Jr., Winter K, Levenback C, et al. Extended-field irradiation and
intracavitary brachytherapy combined with cisplatin chemotherapy for cervical cancer with positive para-aortic or high common iliac lymph nodes: results of ARM 1 of RTOG 0116. Int J Radiat Oncol Biol Phys. 2007;68:1081-1087.
130. Lertsanguansinchai P, Lertbutsayanukul C, Shotelersuk K, et al. Phase III randomized trial comparing LDR and HDR brachytherapy in treatment of cervical carcinoma. Int J Radiat Oncol Biol Phys. 2004;59:1424-1431.
131. Patel FD, Sharma SC, Negi PS, Ghoshal S, Gupta BD. Low dose rate vs. high dose rate brachytherapy in the treatment of carcinoma of the uterine cervix: a clinical trial. Int J Radiat Oncol Biol Phys. 1994;28:335-341.
132. Bodurka-Bevers D, Morris M, Eifel PJ, et al. Posttherapy surveillance of women with cervical cancer: an outcomes analysis. Gynecol Oncol. 2000;78:187-193.
133. Lim KC, Howells RE, Evans AS. The role of clinical follow up in early stage